Abarelix

阿巴瑞克

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAbarelix
Drug Alias Name阿倍瑞克Beta-abarelixAbarelix-depot-Fβ-abarelixAbarelixum +[10
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGonadotropin-releasing hormone receptor antagonists
TargetsGonadotropin-releasing hormone receptor
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2003/11/25
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeL02BX01